G Kuchukhidze1, A M V Kumar2, P de Colombani3, M Khogali4, U Nanava5, H M Blumberg6, R R Kempker6. 1. National Centre for Disease Control and Public Health, Tbilisi, Georgia. 2. International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, New Delhi, India. 3. World Health Organization Regional Office for Europe, Copenhagen, Denmark. 4. Department of Epidemiology, Operational Center of Brussels, Médecins Sans Frontières (MSF), MSF-Belgium, Addis Ababa, Ethiopia. 5. Department of Epidemiology, National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia. 6. Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract
SETTING: Georgia, a country with a high-burden of multi-drug-resistant tuberculosis (MDR-TB). OBJECTIVE: To determine the proportion of loss to follow-up (LFU) among MDR-TB patients treated nationwide from 2009 to 2011, and associated risk factors. DESIGN: Retrospective cohort study involving a review of the National Tuberculosis Programme electronic surveillance database. A Cox proportional hazards model was used to assess risk factors for time to LFU. RESULTS: Among 1593 patients, 458 (29%) were lost to follow-up. A total of 1240 MDR-TB patients were included in the final analysis (845 treatment success, 395 LFU). Over 40% of LFU occurred during the first 8 months of MDR-TB treatment; 40% of patients had not achieved culture conversion at the time of LFU. In multivariate analysis, the factors associated with LFU included male sex, illicit drug use, tobacco use, history of previous anti-tuberculosis treatment, site of TB disease, and place and year of initiating treatment. CONCLUSION: LFU was high among MDR-TB patients in Georgia and posed a significant public health risk, as many were culture-positive at the time of LFU. A multi-pronged approach is needed to address the various patient- and treatment-related characteristics associated with LFU.
SETTING: Georgia, a country with a high-burden of multi-drug-resistant tuberculosis (MDR-TB). OBJECTIVE: To determine the proportion of loss to follow-up (LFU) among MDR-TB patients treated nationwide from 2009 to 2011, and associated risk factors. DESIGN: Retrospective cohort study involving a review of the National Tuberculosis Programme electronic surveillance database. A Cox proportional hazards model was used to assess risk factors for time to LFU. RESULTS: Among 1593 patients, 458 (29%) were lost to follow-up. A total of 1240 MDR-TB patients were included in the final analysis (845 treatment success, 395 LFU). Over 40% of LFU occurred during the first 8 months of MDR-TB treatment; 40% of patients had not achieved culture conversion at the time of LFU. In multivariate analysis, the factors associated with LFU included male sex, illicit drug use, tobacco use, history of previous anti-tuberculosis treatment, site of TB disease, and place and year of initiating treatment. CONCLUSION: LFU was high among MDR-TB patients in Georgia and posed a significant public health risk, as many were culture-positive at the time of LFU. A multi-pronged approach is needed to address the various patient- and treatment-related characteristics associated with LFU.
Entities:
Keywords:
Eastern Europe; MDR-TB; SORT IT; loss to follow-up; operational research
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; A Yedilbayev; M L Rich; J S Mukherjee; J J Furin; S Atwood; P E Farmer; S Keshavjee Journal: Int J Tuberc Lung Dis Date: 2007-12 Impact factor: 2.373
Authors: C Bernard; F Brossier; W Sougakoff; N Veziris; M Frechet-Jachym; N Metivier; A Renvoisé; J Robert; V Jarlier Journal: Euro Surveill Date: 2013-08-15
Authors: Medea Gegia; Iagor Kalandadze; Russel R Kempker; Matthew J Magee; Henry M Blumberg Journal: Int J Infect Dis Date: 2012-03-17 Impact factor: 3.623
Authors: D Falzon; E Jaramillo; H J Schünemann; M Arentz; M Bauer; J Bayona; L Blanc; J A Caminero; C L Daley; C Duncombe; C Fitzpatrick; A Gebhard; H Getahun; M Henkens; T H Holtz; J Keravec; S Keshavjee; A J Khan; R Kulier; V Leimane; C Lienhardt; C Lu; A Mariandyshev; G B Migliori; F Mirzayev; C D Mitnick; P Nunn; G Nwagboniwe; O Oxlade; D Palmero; P Pavlinac; M I Quelapio; M C Raviglione; M L Rich; S Royce; S Rüsch-Gerdes; A Salakaia; R Sarin; D Sculier; F Varaine; M Vitoria; J L Walson; F Wares; K Weyer; R A White; M Zignol Journal: Eur Respir J Date: 2011-08-04 Impact factor: 16.671
Authors: Petros Isaakidis; Helen S Cox; Bhanumati Varghese; Chiara Montaldo; Esdras Da Silva; Homa Mansoor; Joanna Ladomirska; Giovanni Sotgiu; Giovanni B Migliori; Emanuele Pontali; Peter Saranchuk; Camilla Rodrigues; Tony Reid Journal: PLoS One Date: 2011-12-01 Impact factor: 3.240
Authors: Maeve K Lalor; Jane Greig; Sholpan Allamuratova; Sandy Althomsons; Zinaida Tigay; Atadjan Khaemraev; Kai Braker; Oleksander Telnov; Philipp du Cros Journal: PLoS One Date: 2013-11-06 Impact factor: 3.240
Authors: Victoria Panford; Emmanuel Kumah; Collins Kokuro; Prince Owusu Adoma; Michael Afari Baidoo; Adam Fusheini; Samuel Egyakwa Ankomah; Samuel Kofi Agyei; Peter Agyei-Baffour Journal: BMJ Open Date: 2022-07-05 Impact factor: 3.006
Authors: Joel Philip Samuels; Aashna Sood; Jonathon R Campbell; Faiz Ahmad Khan; James Cameron Johnston Journal: Sci Rep Date: 2018-03-21 Impact factor: 4.379
Authors: Soedarsono Soedarsono; Ni Made Mertaniasih; Tutik Kusmiati; Ariani Permatasari; Ni Njoman Juliasih; Cholichul Hadi; Ilham Nur Alfian Journal: BMC Pulm Med Date: 2021-11-10 Impact factor: 3.317
Authors: Thelma E Tupasi; Anna Marie Celina G Garfin; Ekaterina V Kurbatova; Joan M Mangan; Ruth Orillaza-Chi; Leilani C Naval; Glenn I Balane; Ramon Basilio; Alexander Golubkov; Evelyn S Joson; Woo-Jin Lew; Vivian Lofranco; Mariquita Mantala; Stuart Pancho; Jesus N Sarol Journal: Emerg Infect Dis Date: 2016-03 Impact factor: 6.883
Authors: Giorgi Kuchukhidze; Davit Baliashvili; Natalia Adamashvili; Ana Kasradze; Russell R Kempker; Matthew J Magee Journal: Open Forum Infect Dis Date: 2021-03-15 Impact factor: 3.835